How Collaborations Help Abpro's Success

Ian Chan, CEO of Abpro, discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering. Abpro's platform can create novel antibodies at industry-leading speeds, which are then reassembled into custom configurations for therapeutic purposes. They have developed bispecific antibodies, particularly T cell engagers for oncology, which are effective against solid tumors. Abpro's lead oncology program for breast cancer, in partnership with Celltrion, is advancing through clinical phases. Additionally, they have an eye care molecule targeting AMD and DME. The recent NASDAQ listing will aid in accelerating R&D and commercialization efforts. Collaborations, like the one with Celltrion, have been instrumental in the company's success.

How are the collaborations that Abpro has formed contributing to the company's success?

They've been great. We've historically have had a variety of them. South Korean being the most recent. We seek to form Win-Win collaborations all the time, so one plus one equals three. Like both parties are benefiting as a result, and the ones that work really well, and are ones where we bring complimentary capabilities. In this case, Celltrion brought a lot of the HER2 expertise because of their approved HER2 biosimilar they had significant manufacturing and worldwide clinical capabilities. There are big companies, so they have the resources, but yet they're nimble enough where they can move very quickly. And then on our end, they were really looking to get into novel biologics like we brought a lot of the front-end capabilities, as far as being a discovery engine, being very nimble on the R&D side, it kind of worked well in that way, so nobody's going to step on each other's throats. It's been a been a great partnership so far